FDA approves new drug for schizophrenia, bipolar disorder

September 18, 2015
FDA approves new drug for schizophrenia, bipolar disorder
Vraylar is an atypical antipsychotic taken once a day.

(HealthDay)—A new antipsychotic drug to treat schizophrenia and bipolar disorder in adults has been approved by the U.S. Food and Drug Administration.

The drug, Vraylar (cariprazine), is a capsule taken once a day.

"Schizophrenia and can be disabling and can greatly interfere with day-to-day activities," Dr. Mitchell Mathis, director of the division of psychiatry products in the FDA's Center for Drug Evaluation and Research, said in an agency news release.

"It is important to have a variety of treatment options available to patients with mental illnesses so that treatment plans can be tailored to meet a patient's individual needs," Mathis said.

Schizophrenia, a chronic and disabling brain disorder that usually develops in early adulthood, occurs in 1 percent of the general population, according to the U.S. National Institute of Mental Health. People with the condition often see or hear things that are not there. They are also withdrawn or paranoid, believing others are trying to read their mind or control their thoughts.

Vraylar belongs to a class of drugs known as atypical antipsychotics. Others in this group include Abilify (aripiprazole), Seroquel (quetiapine) and Risperdal (risperidone).

The drug's effectiveness in treating schizophrenia was tested among more than 1,750 patients in three six-week clinical trials. It was shown to reduce schizophrenia symptoms compared to the placebo. The drug's maker, Forest Labs, and distributor, Actavis Pharma, are based in New Jersey.

The most commonly reported side effects in the schizophrenia trials were tremor, slurred speech and involuntary muscle movements.

Bipolar disorder, also known as manic-depressive illness, leads to dramatic mood swings or shifts in energy and activity levels. People with bipolar disorder have alternating episodes of depression and mania, or "highs," characterized by irritability, increased activity, restlessness, impulsive behavior and racing thoughts. Almost 3 percent of U.S. adults have bipolar disorder, the institute says.

In three three-week trials involving more than 1,000 bipolar patients, Vraylar reduced disorder symptoms, the FDA said.

The most common drug-related side effects in the bipolar disorder trial included tremor, slurred speech, an urge to move (akathisia), indigestion, vomiting, drowsiness and restlessness.

All FDA-approved drugs for and bipolar disorder must carry a black box warning indicating an increased risk of death if these drugs are used by older people with dementia-related psychosis, the agency noted.

Explore further: First generic Abilify approved

More information: The U.S. National Institute of Mental Health has more about mental health medications.

Related Stories

First generic Abilify approved

April 30, 2015
(HealthDay)—The first generic versions of the atypical antipsychotic drug Abilify (aripiprazole) have been approved by the U.S. Food and Drug Administration to treat schizophrenia or bipolar disorder.

FDA approves new drug for schizophrenia, major depression

July 13, 2015
(HealthDay)—A new drug to treat schizophrenia and depression has been approved by the U.S. Food and Drug Administration.

How to tell the difference between bipolar disorder and depression

August 5, 2015
Many patients with bipolar disorder, a debilitating mental condition that can take a person from the sluggishness of severe depression to super-human energy levels, are often misdiagnosed as having major depressive disorder, ...

Borderline personality disorder as debilitating as bipolar disorder

April 23, 2015
The deterioration of psychiatric and physical health caused by borderline personality disorder (BPD) rivals that of bipolar disorder, according to Mark Zimmerman, M.D., a researcher at Rhode Island Hospital. His research ...

For women with bipolar disorder, sleep quality affects mood

June 30, 2015
Poor sleep is associated with negative mood in women with bipolar disorder, according to researchers at Penn State College of Medicine and University of Michigan Medical School.

How cannabis use affects people with Bipolar Disorder

March 13, 2015
The first study to examine the use of cannabis in the context of daily life among people with Bipolar Disorder has shown how the drug is linked to increases in both manic and depressive symptoms.

Recommended for you

Stress in pregnancy linked to changes in infant's nervous system, less smiling, less resilience

November 23, 2017
Maternal stress during the second trimester of pregnancy may influence the nervous system of the developing child, both before and after birth, and may have subtle effects on temperament, resulting in less smiling and engagement, ...

Domestic violence turns women off masculine men

November 23, 2017
Women who are afraid of violence within partnerships prefer more feminine men, according to new research carried out by scientists at the University of St Andrews.

Study finds infection and schizophrenia symptom link

November 22, 2017
If a mother's immune system is activated by infection during pregnancy, it could result in critical cognitive deficits linked to schizophrenia in her offspring, a University of Otago study has revealed.

Schizophrenia drug development may be 'de-risked' with new research tool

November 22, 2017
Researchers at Columbia University Medical Center (CUMC) and the New York State Psychiatric Institute (NYSPI) have identified biomarkers that can aid in the development of better treatments for schizophrenia.

Self-harm, suicide attempts climb among US girls, study says

November 21, 2017
Attempted suicides, drug overdoses, cutting and other types of self-injury have increased substantially in U.S. girls, a 15-year study of emergency room visits found.

Car, stroller, juice: Babies understand when words are related

November 20, 2017
The meaning behind infants' screeches, squeals and wails may frustrate and confound sleep-deprived new parents. But at an age when babies cannot yet speak to us in words, they are already avid students of language.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

oliverlu70
not rated yet Sep 19, 2015
"Schizophrenia, a chronic and disabling brain disorder..."

The piece should read:

"The schizophrenias, a class of disorders hypothesized to be based in the brain and often (but not always) characterized by chronicity..."

Also how is the new drug better than already-available choices?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.